JP2021500852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021500852A5 JP2021500852A5 JP2020509107A JP2020509107A JP2021500852A5 JP 2021500852 A5 JP2021500852 A5 JP 2021500852A5 JP 2020509107 A JP2020509107 A JP 2020509107A JP 2020509107 A JP2020509107 A JP 2020509107A JP 2021500852 A5 JP2021500852 A5 JP 2021500852A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- antigen
- peptide
- tcr
- abp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims description 292
- 108091000831 antigen binding proteins Proteins 0.000 claims description 292
- 108091008874 T cell receptors Proteins 0.000 claims description 192
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 190
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 119
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 108
- 210000004027 cell Anatomy 0.000 claims description 52
- 238000000034 method Methods 0.000 claims description 38
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims description 32
- 239000000427 antigen Substances 0.000 claims description 32
- 102000036639 antigens Human genes 0.000 claims description 32
- 108091007433 antigens Proteins 0.000 claims description 32
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 239000012634 fragment Substances 0.000 claims description 22
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 16
- 230000021615 conjugation Effects 0.000 claims description 16
- 150000007523 nucleic acids Chemical group 0.000 claims description 16
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 14
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 claims description 12
- 108010075704 HLA-A Antigens Proteins 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 12
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 12
- 206010028980 Neoplasm Diseases 0.000 claims description 11
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 11
- 239000013598 vector Substances 0.000 claims description 10
- 230000004068 intracellular signaling Effects 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 8
- 238000002823 phage display Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 238000005259 measurement Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 4
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 4
- 239000011324 bead Substances 0.000 claims description 4
- 229960002685 biotin Drugs 0.000 claims description 4
- 235000020958 biotin Nutrition 0.000 claims description 4
- 239000011616 biotin Substances 0.000 claims description 4
- 210000000265 leukocyte Anatomy 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 239000011541 reaction mixture Substances 0.000 claims description 4
- 210000004881 tumor cell Anatomy 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 239000007801 affinity label Substances 0.000 claims description 3
- 238000010367 cloning Methods 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 108700028369 Alleles Proteins 0.000 claims description 2
- 244000303258 Annona diversifolia Species 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims description 2
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 claims description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims description 2
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 229920002684 Sepharose Polymers 0.000 claims description 2
- 102000007562 Serum Albumin Human genes 0.000 claims description 2
- 108010071390 Serum Albumin Proteins 0.000 claims description 2
- 108010090804 Streptavidin Proteins 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000004113 cell culture Methods 0.000 claims description 2
- 239000006143 cell culture medium Substances 0.000 claims description 2
- 210000004748 cultured cell Anatomy 0.000 claims description 2
- 238000000684 flow cytometry Methods 0.000 claims description 2
- 239000007850 fluorescent dye Substances 0.000 claims description 2
- 210000004408 hybridoma Anatomy 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 230000031146 intracellular signal transduction Effects 0.000 claims description 2
- 238000007885 magnetic separation Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 238000002818 protein evolution Methods 0.000 claims description 2
- 239000011535 reaction buffer Substances 0.000 claims description 2
- 108020003175 receptors Proteins 0.000 claims description 2
- 102000005962 receptors Human genes 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 238000000926 separation method Methods 0.000 claims description 2
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 230000011664 signaling Effects 0.000 claims description 2
- 230000009258 tissue cross reactivity Effects 0.000 claims description 2
- 230000009466 transformation Effects 0.000 claims description 2
- -1 wells Substances 0.000 claims description 2
- 210000005253 yeast cell Anatomy 0.000 claims description 2
- 241000724791 Filamentous phage Species 0.000 claims 1
- 102000018146 globin Human genes 0.000 claims 1
- 108060003196 globin Proteins 0.000 claims 1
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 1
- 102100030758 Sex hormone-binding globulin Human genes 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547146P | 2017-08-18 | 2017-08-18 | |
| US62/547,146 | 2017-08-18 | ||
| US201762581368P | 2017-11-03 | 2017-11-03 | |
| US62/581,368 | 2017-11-03 | ||
| PCT/US2018/046997 WO2019036688A1 (en) | 2017-08-18 | 2018-08-17 | ANTIGEN BINDING PROTEINS TARGETING SHARED ANTIGENS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021500852A JP2021500852A (ja) | 2021-01-14 |
| JP2021500852A5 true JP2021500852A5 (enExample) | 2021-09-30 |
Family
ID=65362959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020509107A Pending JP2021500852A (ja) | 2017-08-18 | 2018-08-17 | 共有抗原を標的にする抗原結合タンパク質 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20210147550A1 (enExample) |
| EP (1) | EP3668539A4 (enExample) |
| JP (1) | JP2021500852A (enExample) |
| KR (2) | KR20200084320A (enExample) |
| CN (1) | CN111328288B (enExample) |
| AU (1) | AU2018318303A1 (enExample) |
| CA (1) | CA3072816A1 (enExample) |
| IL (1) | IL272466A (enExample) |
| MX (2) | MX2020001879A (enExample) |
| SG (1) | SG11202001368SA (enExample) |
| WO (1) | WO2019036688A1 (enExample) |
| ZA (1) | ZA202001285B (enExample) |
Families Citing this family (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| HRP20211754T1 (hr) | 2014-12-23 | 2022-03-04 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacije peptida za upotrebu u imunoterapiji protiv hepatocelularnog karcinoma (hcc) i drugih rakova |
| US9422547B1 (en) | 2015-06-09 | 2016-08-23 | Gigagen, Inc. | Recombinant fusion proteins and libraries from immune cell repertoires |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MX2019013517A (es) | 2017-05-24 | 2020-08-17 | Pandion Operations Inc | Inmunotolerancia dirigida. |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| KR20250097989A (ko) * | 2017-12-28 | 2025-06-30 | 그릿스톤 바이오, 인코포레이티드 | 공통 항원을 표적화하는 항원-결합 단백질 |
| EP3784255B1 (en) * | 2018-04-19 | 2025-09-17 | Board of Regents, The University of Texas System | T cell receptors with mage-b2 specificity and uses thereof |
| WO2020037302A1 (en) * | 2018-08-17 | 2020-02-20 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared antigens |
| CN111138521B (zh) * | 2018-11-06 | 2022-10-28 | 香雪生命科学技术（广东）有限公司 | 源自于afp抗原的短肽 |
| CN111138522B (zh) * | 2018-11-06 | 2023-01-24 | 香雪生命科学技术（广东）有限公司 | 衍生自afp的肿瘤抗原短肽 |
| GB2596461B (en) * | 2019-02-20 | 2023-09-27 | Fred Hutchinson Cancer Center | Binding proteins specific for RAS neoantigens and uses thereof |
| EP3941491A4 (en) | 2019-03-21 | 2023-03-29 | Gigamune, Inc. | ENGINEERED CELLS EXPRESSING ANTIVIRAL T-CELL RECEPTORS AND METHODS OF USE |
| EP3714941A1 (en) * | 2019-03-27 | 2020-09-30 | Medigene Immunotherapies GmbH | Mage-a4 tcrs |
| US20200318068A1 (en) * | 2019-04-04 | 2020-10-08 | Immatics US, Inc. | Use of retinoic acid in t-cell manufacturing |
| AU2020253491A1 (en) | 2019-04-05 | 2021-10-28 | Rootpath Genomics, Inc. | Compositions and methods for T-cell receptor gene assembly |
| WO2020227091A1 (en) * | 2019-05-03 | 2020-11-12 | Gigamune, Inc. | Engineered cells expressing anti-tumor t cell receptors and methods of use thereof |
| EP3972992A4 (en) | 2019-05-20 | 2023-07-19 | Pandion Operations, Inc. | MADCAM TARGETED IMMUNOTLERANCE |
| EP3760217A1 (en) * | 2019-07-01 | 2021-01-06 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Cd5 specific t cell receptor cell or gene therapy |
| EP3997116A1 (en) * | 2019-07-09 | 2022-05-18 | Medigene Immunotherapies GmbH | Magea10 specific t cell receptors and their use |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| CN112300261B (zh) * | 2019-07-23 | 2023-03-17 | 香雪生命科学技术（广东）有限公司 | 一种衍生自afp的肿瘤抗原短肽 |
| CN114728179A (zh) * | 2019-08-19 | 2022-07-08 | 潘迪恩运营公司 | 利用pd-1激动剂的靶向免疫耐受 |
| WO2021048381A1 (en) * | 2019-09-13 | 2021-03-18 | Evaxion Biotech Aps | Method for identifying stable mhc binding peptides using mass spectrometry |
| WO2021076939A1 (en) * | 2019-10-18 | 2021-04-22 | Board Of Regents, The University Of Texas System | Hla-restricted vcx/y peptides and t cell receptors and use thereof |
| WO2021092094A1 (en) * | 2019-11-04 | 2021-05-14 | Gritstone Oncology, Inc. | Antigen-binding proteins targeting shared neoantigens |
| AU2020384374A1 (en) * | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| CN112898399A (zh) * | 2019-12-03 | 2021-06-04 | 香雪生命科学技术（广东）有限公司 | 源自于afp抗原的短肽 |
| CN115960205A (zh) * | 2019-12-13 | 2023-04-14 | 南京大户生物科技有限公司 | 原发性肝癌相关抗原的胸腺依赖性淋巴细胞抗原表位肽及其应用 |
| CN113072636B (zh) * | 2020-01-06 | 2024-05-28 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的t细胞受体及其编码序列 |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| CN113321725B (zh) * | 2020-02-28 | 2024-06-11 | 香雪生命科学技术（广东）有限公司 | 一种识别afp的t细胞受体 |
| CN113321727B (zh) * | 2020-02-28 | 2024-04-09 | 香雪生命科学技术（广东）有限公司 | 一种识别afp抗原短肽的t细胞受体及其编码序列 |
| JP2023517889A (ja) * | 2020-03-10 | 2023-04-27 | マサチューセッツ インスティテュート オブ テクノロジー | ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法 |
| CN113493505A (zh) * | 2020-03-20 | 2021-10-12 | 香雪生命科学技术（广东）有限公司 | 识别afp抗原的高亲和力tcr |
| JP2023527293A (ja) * | 2020-05-19 | 2023-06-28 | アムジエン・インコーポレーテツド | Ｍａｇｅｂ２結合構築物 |
| CN116096740A (zh) * | 2020-06-09 | 2023-05-09 | 得克萨斯州大学系统董事会 | 经改造t细胞受体和使用方法 |
| JP7391208B2 (ja) | 2020-07-08 | 2023-12-04 | エルジー エナジー ソリューション リミテッド | バッテリーパック及びそれを含む自動車 |
| WO2022026772A1 (en) * | 2020-07-29 | 2022-02-03 | Gritstone Bio, Inc. | Engineered multi-specific antibodies and related methods of use and manufacture |
| CN116472050A (zh) * | 2020-09-04 | 2023-07-21 | 美国卫生和人力服务部 | 识别p53中r273c或y220c突变的t细胞受体 |
| MX2023003371A (es) * | 2020-09-24 | 2023-04-26 | Medigene Immunotherapies Gmbh | Receptores de células t específicos de mage-a3 y su uso. |
| IL301543A (en) * | 2020-09-24 | 2023-05-01 | Medigene Immunotherapies Gmbh | Prame specific t cell receptors and uses thereof |
| WO2022087380A1 (en) * | 2020-10-23 | 2022-04-28 | Rootpath Genomics, Inc. | Compositions and methods for t-cell receptor identification |
| KR20230104220A (ko) * | 2020-11-05 | 2023-07-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 항원을 표적화하는 조작된 t 세포 수용체 및 사용 방법 |
| WO2022155503A1 (en) * | 2021-01-14 | 2022-07-21 | Gritstone Bio, Inc. | Multi-specific antibodies and methods of use |
| US12053517B2 (en) | 2021-01-14 | 2024-08-06 | Gilead Sciences, Inc. | HIV vaccines and methods of using |
| US20240239864A1 (en) * | 2021-02-16 | 2024-07-18 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Hla class i-restricted t cell receptors against cd22 |
| JP2024509910A (ja) | 2021-03-09 | 2024-03-05 | シーディアール－ライフ・アクチェンゲゼルシャフト | Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 |
| EP4304725A1 (en) | 2021-03-09 | 2024-01-17 | CDR-Life AG | Rabbit-derived antigen binding protein nucleic acid libraries |
| EP4313139A4 (en) * | 2021-03-29 | 2025-07-02 | Univ Texas | MODIFIED T-CELL PEPTIDES AND RECEPTORS TARGETING SARS-CoV-2 ANTIGENS AND METHODS OF USE |
| WO2022216574A1 (en) * | 2021-04-05 | 2022-10-13 | Janssen Biotech, Inc. | Calr and jak2 t-cell receptors |
| WO2022229966A1 (en) | 2021-04-29 | 2022-11-03 | Yeda Research And Development Co. Ltd. | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same |
| EP4091627A1 (en) * | 2021-05-21 | 2022-11-23 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Tcr constructs specific for magea4-derived epitopes |
| WO2022251283A1 (en) * | 2021-05-25 | 2022-12-01 | Memorial Sloan-Kettering Cancer Center | T cell receptors targeting ras mutations and uses thereof |
| US20250073323A1 (en) * | 2021-08-06 | 2025-03-06 | Anyadi, Llc | Process for producing personalized cancer immunotherapy |
| WO2023050063A1 (zh) * | 2021-09-28 | 2023-04-06 | 溧阳瑅赛生物医药有限公司 | 一种识别hla-a*02:01/e629-38的tcr及其应用 |
| JP2024539273A (ja) * | 2021-10-25 | 2024-10-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｍａｇｅ－ａ４抗原を標的とするペプチドおよび操作されたｔ細胞受容体ならびに使用の方法 |
| US20240415886A1 (en) * | 2021-10-29 | 2024-12-19 | Yafei Hou | T cell receptor recognizing r175h mutation in p53 and its application |
| WO2023148494A1 (en) * | 2022-02-03 | 2023-08-10 | University College Cardiff Consultants Limited | Novel t-cell receptor |
| CA3244259A1 (en) * | 2022-02-23 | 2023-08-31 | Aloe Therapeutics Inc | Compositions and methods for modulating the immune system |
| NL2031118B1 (en) * | 2022-03-01 | 2023-09-07 | Academisch Ziekenhuis Leiden | T cell receptors directed against transcription factor wt1 and uses thereof |
| CN116836261A (zh) * | 2022-03-24 | 2023-10-03 | 香雪生命科学技术（广东）有限公司 | 一种识别mage-a4抗原的高亲和力tcr及其序列和应用 |
| CN117264043B (zh) * | 2022-06-14 | 2024-05-10 | 上海镔铁生物科技有限责任公司 | 靶向kras g12v突变多肽的t细胞受体及其用途 |
| KR20250067130A (ko) | 2022-09-14 | 2025-05-14 | 씨디알-라이프 아게 | Mage-a4 펩티드 이중 t 세포 연결체 |
| CA3268204A1 (en) * | 2022-10-05 | 2024-04-11 | Tscan Therapeutics Inc | MAGEA1 IMMUNOGENEOUS PEPTIDES, MAGEA1 IMMUNOGENEOUS PEPTIDE-BINDING PROTEINS, AND THEIR USES |
| CN116158405B (zh) * | 2023-01-30 | 2024-04-26 | 西北农林科技大学 | 一种提高奶山羊后代母羔率的方法 |
| WO2025064738A1 (en) * | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025093596A2 (en) * | 2023-10-30 | 2025-05-08 | T-Knife Gmbh | Antigen recognizing construct capable of binding to a preferentially expressed antigen in melanoma (prame) peptide and a t cell receptor (tcr) having antigenic specificity for prame as well as corresponding nucleic acid sequence, vector, host cell, pharmaceutical composition and kit |
| CN118256604B (zh) * | 2024-04-16 | 2024-11-19 | 华中科技大学 | 一种利用人工抗原呈递细胞进行免疫原性肿瘤新抗原筛选与鉴定方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030017134A1 (en) * | 2001-06-19 | 2003-01-23 | Technion Research And Development Foundation Ltd. | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
| CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| EP2356270B1 (en) * | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
| SI2755997T1 (sl) * | 2011-09-15 | 2018-11-30 | The United States of America, as represented by Secretary, Department of Health and Human Services, Office of Technology Transfer, National Institutes of Health | T-celični receptorji, ki prepoznajo HLA-A1- ali HLA-CW7-omejeni mage |
| WO2013130814A1 (en) * | 2012-02-29 | 2013-09-06 | Ambrx, Inc. | Novel prodrug containing molecule compostions and their uses |
| TWI702229B (zh) * | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| CN107921127B (zh) * | 2015-05-22 | 2022-04-08 | 纪念斯隆-凯特琳癌症中心 | 对于prame肽具有特异性的t细胞受体样抗体 |
| GB201520559D0 (en) * | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017124001A2 (en) * | 2016-01-14 | 2017-07-20 | Memorial Sloan-Kettering Cancer Center | T cell receptor-like antibodies specific for foxp3-derived peptides |
-
2018
- 2018-08-17 MX MX2020001879A patent/MX2020001879A/es unknown
- 2018-08-17 CN CN201880064852.3A patent/CN111328288B/zh active Active
- 2018-08-17 KR KR1020207007862A patent/KR20200084320A/ko not_active Ceased
- 2018-08-17 US US16/639,073 patent/US20210147550A1/en not_active Abandoned
- 2018-08-17 EP EP18846867.2A patent/EP3668539A4/en active Pending
- 2018-08-17 AU AU2018318303A patent/AU2018318303A1/en not_active Abandoned
- 2018-08-17 WO PCT/US2018/046997 patent/WO2019036688A1/en not_active Ceased
- 2018-08-17 CA CA3072816A patent/CA3072816A1/en active Pending
- 2018-08-17 SG SG11202001368SA patent/SG11202001368SA/en unknown
- 2018-08-17 KR KR1020257008027A patent/KR20250040097A/ko active Pending
- 2018-08-17 JP JP2020509107A patent/JP2021500852A/ja active Pending
-
2020
- 2020-02-04 IL IL272466A patent/IL272466A/en unknown
- 2020-02-17 MX MX2025011582A patent/MX2025011582A/es unknown
- 2020-02-28 ZA ZA2020/01285A patent/ZA202001285B/en unknown
-
2022
- 2022-12-13 US US18/065,223 patent/US20230382997A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021500852A5 (enExample) | ||
| JP7781243B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| TWI659969B (zh) | 一種抗ｐｄ－１的單株抗體及其獲得方法 | |
| US20200024358A1 (en) | Trispecific antigen binding proteins | |
| JP2022550832A (ja) | Ｃｄ３を標的とする抗体、二重特異性抗体及びその使用 | |
| KR20200099137A (ko) | 세포 요법 및 감마 세크레타제 억제제의 조합 | |
| TW201922784A (zh) | ４﹘１ｂｂ抗體及其製備方法和應用 | |
| JP2018502050A5 (enExample) | ||
| JP2020525533A (ja) | 細胞により発現される生物学的活性を調節する抗体 | |
| JP2021528382A (ja) | 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段 | |
| CA3200317A1 (en) | Multitargeting bispecific antigen-binding molecules of increased selectivity | |
| JP2019512207A5 (enExample) | ||
| JP2020530859A (ja) | 免疫調節剤としてのｃｄ９６結合剤 | |
| JP2022531242A (ja) | 抗ｈｖｅｍ抗体およびそれらの使用 | |
| BR112020001180A2 (pt) | proteínas de ligação a antígenos que se ligam a 5t4 e 4-1bb e composições e métodos relacionados | |
| US20250353914A1 (en) | Antigen-binding proteins and related methods of use | |
| JP2024509557A (ja) | ＮＫｐ４６に対する抗体とその応用 | |
| JPWO2021097365A5 (enExample) | ||
| JP2023530083A (ja) | Ｈｌａ－ｇ及び別の抗原に対して結合特異性を有する二重特異性免疫細胞エンゲージャー | |
| CN116710136A (zh) | Prame结合性分子 | |
| TW202417496A (zh) | 分離的抗原結合蛋白及其用途 | |
| CN119278213A (zh) | 针对ctla-4的抗体及其使用方法 | |
| US11896619B2 (en) | Compositions and methods for immunotherapy of NPM1c-positive cancer | |
| CN114634567B (zh) | 一种免疫调节剂的开发及其应用 | |
| US20250082753A1 (en) | Chimeric receptors |